BIBLIOGRAPHY
1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et
al. Colorectal Cancer Statistics , 2017. 2017;67(3):177–93.
2. Puerta-García E. Pharmacogenomics Molecular biomarkers in colorectal.
Pharmacogenetics. 2015;
3. Passiglia F, Bronte G, Bazan V, Galvano A, Vincenzi B, Russo A.
Critical Reviews in Oncology / Hematology Can KRAS and BRAF mutations
limit the benefit of liver resection in metastatic colorectal cancer
patients ? A systematic review and. Crit Rev Oncol / Hematol. Elsevier
Ireland Ltd; 2016;99:150–7.
4. Carón RW, Yacoub A, Zhu X, Mitchell C, Han SI, Sasazuki T, et al.
H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is
heregulin dependent. Mol Cancer Ther [Internet]. 2005 Feb [cited
2018 Feb 13];4(2):243–55. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/15713896
5. Ichii S, Nagase H, Mori T, Baba S, Nakamura Y. A novel mutation of
the APC (adenomatous polyposis coli) gene in a familial adenomatous
polyposis (FAP) patient and presymptomatic diagnosis using PCR. Hum Mol
Genet [Internet]. 1993 May [cited 2018 Feb 13];2(5):597.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/8390900
6. Takashima A, Faller D V. Targeting the RAS oncogene. Expert Opin Ther
Targets [Internet]. 2013 May 30 [cited 2018 Feb
13];17(5):507–31. Available from:
http://www.tandfonline.com/doi/full/10.1517/14728222.2013.764990
7. Brink M, Weijenberg MP, de Goeij AFPM, Roemen GMJM, Lentjes MHFM, de
Bruïne AP, et al. Meat consumption and K-ras mutations in sporadic colon
and rectal cancer in The Netherlands Cohort Study. Br J Cancer
[Internet]. 2005 Apr 11 [cited 2018 Feb 13];92(7):1310–20.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/15812479
8. Roock W De, Claes B, Bernasconi D, Schutter J De, Biesmans B,
Fountzilas G, et al. on the effi cacy of cetuximab plus chemotherapy in
chemotherapy-refractory metastatic colorectal cancer : a retrospective
consortium analysis. 2010;11(August):753–62.
9. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al.
Mutations of the BRAF gene in human cancer. Nature [Internet]. 2002
Jun 27 [cited 2018 Feb 13];417(6892):949–54. Available from:
http://www.nature.com/articles/nature00766
10. Laurent-puig P, Cayre A, Manceau G, Buc E, Bachet J, Lecomte T, et
al. J OURNAL OF C LINICAL O NCOLOGY Analysis of PTEN , BRAF , and EGFR
Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS
Metastatic Colon Cancer. 2013;27(35).
11. Pandurangan AK. MINI-REVIEW Potential Targets for Prevention of
Colorectal Cancer : a Focus on PI3K / Akt / mTOR and Wnt Pathways.
2013;14:2201–5.
12. Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M,
et al. Panitumumab–FOLFOX4 Treatment and RAS Mutations in
Colorectal Cancer. N Engl J Med [Internet]. 2013;369(11):1023–34.
Available from: http://www.nejm.org/doi/10.1056/NEJMoa1305275
13. Osumi H, Shinozaki E, Osako M, Kawazoe Y, Oba M. Cetuximab treatment
for metastatic colorectal cancer with KRAS p . G13D mutations improves
progression-free survival. 2015;1053–7.
14. Yu Imamura, Teppei Morikawa, Xiaoyun Liao, Paul Lochhead, Aya
Kuchiba M, Yamauchi, Zhi Rong Qian, Reiko Nishihara, Jeffrey A.
Meyerhardt KMH, Charles S. Fuchs and SO. Specific Mutations in KRAS
Codons 12 and 13, and Patient Prognosis in 1075 BRAF-wild-type
Colorectal Cancers. Clin Cancer Res. 2012;18(17):4753–4763.
15. Edge SB, Compton CC. The American Joint Committee on Cancer : the
7th Edition of the AJCC Cancer Staging Manual and the Future of TNM.
2010;1471–4.
16. Report T. Investigation of the freely available easy-to-use software
“ EZR ” for medical statistics. 2013;(November 2012):452–8.
17. Ciardiello F, Tortora G. EGFR Antagonists in Cancer Treatment. N
Engl J Med. 2008;358:1160–74.
18. Gajate P, Sastre J, Bando I, Alonso T, Cillero L, Sanz J, et al.
Influence of KRAS p . G13D Mutation in Patients With Metastatic
Colorectal Cancer Treated With Cetuximab. CLCC. Elsevier;
2012;11(4):291–6.
19. Sartore-bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M,
Artale S, et al. PIK3CA Mutations in Colorectal Cancer Are Associated
with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies.
2009;(5):1851–8.
20. Jean-Yves Douillard, M.D., Ph.D., Kelly S. Oliner, Ph.D., Salvatore
Siena MD, Josep Tabernero, M.D., Ronald Burkes, M.D., Mario Barugel MD,
Yves Humblet, M.D., Ph.D., Gyorgy Bodoky, M.D. PD, David Cunningham,
M.D., Jacek Jassem, M.D., Ph.D., Fernando Rivera, M.D. PD, Ilona
Kocákova, M.D., Ph.D., Paul Ruff, M.D., Maria Błasińska-Morawiec MD,
Martin Šmakal, M.D., Jean Luc Canon, M.D., Mark Rother MD, et al.
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N
Engl J Med. 2013;369:1023–34.
21. Christos S. Karapetis, M.D., Shirin Khambata-Ford, Ph.D., Derek J.
Jonker, M.D., Chris J. O’Callaghan PD, Dongsheng Tu, Ph.D., Niall C.
Tebbutt, Ph.D., R. John Simes, M.D., Haji Chalchal, M.D., Jeremy D.
Shapiro MD, Sonia Robitaille, M.Sc., Timothy J. Price, M.D., Lois
Shepherd, M.D.C.M., Heather-Jane Au MD, Christiane Langer, M.D., Malcolm
J. Moore, M.D., and John R. Zalcberg, M.D. P. K-ras Mutations and
Benefit from Cetuximab in Advanced Colorectal Cancer. N Engl J Med.
2008;359:1757–65.
22. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Cutsem E
Van. J OURNAL OF C LINICAL O NCOLOGY Association of KRAS G13D Tumor
Mutations With Outcome in Patients With Metastatic Colorectal Cancer
Treated With First-Line Chemotherapy With or Without Cetuximab.
2015;30(29).
23. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E,
Ciardiello F. Implications for KRAS status and EGFR-targeted therapies
in metastatic CRC. Nat Rev Clin Oncol [Internet]. Nature Publishing
Group; 2009;6(9):519–27. Available from:
http://dx.doi.org/10.1038/nrclinonc.2009.111
24. Van Krieken JHJM, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman
FT, et al. KRAS mutation testing for predicting response to anti-EGFR
therapy for colorectal carcinoma: Proposal for an European quality
assurance program. Virchows Arch. 2008;453(5):417–31.
25. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes
DF, et al. American society of clinical oncology provisional clinical
opinion: Testing for KRAS gene mutations in patients with metastatic
colorectal carcinoma to predict response to anti-epidermal growth factor
receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091–6.
26. Metro G, Finocchiaro G, Cappuzzo F. Anti-cancer therapy with EGFR
inhibitors: factors of prognostic and predictive significance. Ann Oncol
[Internet]. 2006;17 Suppl 2(Supplement 2):ii42-45. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/16608980
27. Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, et
al. Prognostic vs predictive molecular biomarkers in colorectal cancer:
Is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer
Treat Rev [Internet]. Elsevier Ltd; 2010;36(SUPPL. 3):S56–61.
Available from: http://dx.doi.org/10.1016/S0305-7372(10)70021-9
28. Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110
␣ of phosphatidylinositol 3-kinase induce gain of function by different
mechanisms. 2008;